LABUDirexion Daily S&P Biotech Bull 3X Shares
Seeks daily investment results of 300% of the daily performance of the Index.
By Direxion Funds · Launched 2015
Annual Cost
0.96%
#5,141 of 6,040 · expensive
Fund Size
$571M
#1,567 of 6,040 · large
Return (1Y)
+251.4%
Track Record
11 years
#1,290 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$22,685+126.8%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Leveraged
Sector
Health careIndex tracked
S&P Biotechnology Select Industry Index
Holdings
By weightConcentration
synthetic exposure — holdings shown are derivatives collateral, not the fund's positions
DREYFUS GOVERNMENT CASH MANAGE
7.9%
GOLDMAN FINANCIAL
6.7%
N/A
2.8%
GOLDMAN SACHS LIQ ES FD A
1.8%
Apellis Pharmaceuticals Inc
1.5%
N/A
1.5%
Revolution Medicines Inc
1.4%
Travere Therapeutics Inc
1.3%
ARROWHEAD PHARMACEUTICALS INC
1.2%
Twist Bioscience Corporation
1.2%
Asset allocation
Other
80.1%
Stocks
26.0%
By sector
Healthcare
99.3%
Financial Services
0.7%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
83.5%High
Year-on-year price swings
Max drawdown
-99.0%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.79Decent risk-adjusted returns
Sortino (3Y)
1.16Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks daily investment results of 300% of the daily performance of the Index.
- Strategy
- Invests primarily in U.S.-based biotechnology companies with a float-adjusted market capitalization above $300 million, aiming for 3X daily leveraged exposure to the Index. The Fund is non-diversified and rebalances daily to maintain its investment objective.
- Inception date
- May 28, 2015
- Fund family
- Direxion Funds
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save LABU to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18